TY - JOUR
T1 - Impact of accumulative smoking exposure and chronic obstructive pulmonary disease on COVID-19 outcomes
T2 - report based on findings from the Japan COVID-19 task force
AU - Japan COVID-19 Task Force
AU - Watase, Mayuko
AU - Masaki, Katsunori
AU - Chubachi, Shotaro
AU - Namkoong, Ho
AU - Tanaka, Hiromu
AU - Lee, Ho
AU - Fukushima, Takahiro
AU - Otake, Shiro
AU - Nakagawara, Kensuke
AU - Kusumoto, Tatsuya
AU - Asakura, Takanori
AU - Kamata, Hirofumi
AU - Ishii, Makoto
AU - Hasegawa, Naoki
AU - Oyamada, Yoshitaka
AU - Harada, Norihiro
AU - Ueda, Tetsuya
AU - Ueda, Soichiro
AU - Ishiguro, Takashi
AU - Arimura, Ken
AU - Saito, Fukuki
AU - Yoshiyama, Takashi
AU - Nakano, Yasushi
AU - Mutoh, Yoshikazu
AU - Suzuki, Yusuke
AU - Edahiro, Ryuya
AU - Sano, Hirohito
AU - Sato, Yasunori
AU - Okada, Yukinori
AU - Koike, Ryuji
AU - Kitagawa, Yuko
AU - Tokunaga, Katsushi
AU - Kimura, Akinori
AU - Imoto, Seiya
AU - Miyano, Satoru
AU - Ogawa, Seishi
AU - Kanai, Takanori
AU - Fukunaga, Koichi
N1 - Funding Information:
This study was supported by Japan Agency for Medical Research and Development (AMED; JP20nk0101612, JP20fk0108415, JP21jk0210034, JP21km0405211, and JP21km0405217), Japan Science and Technology Agency Core Research for Evolutional Science and Technology (JST CREST; JPMJCR20H2), Ministry of Health, Labour and Welfare (MHLW; 20CA2054), Takeda Science Foundation, Mitsubishi Foundation, and the Bioinformatics Initiative of Osaka University Graduate School of Medicine, Osaka University. The funding agencies had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
Funding Information:
The authors have no competing interests to declare. This study was supported by Japan Agency for Medical Research and Development (AMED; JP20nk0101612, JP20fk0108415, JP21jk0210034, JP21km0405211, and JP21km0405217), Japan Science and Technology Agency Core Research for Evolutional Science and Technology (JST CREST; JPMJCR20H2), Ministry of Health, Labour and Welfare (MHLW; 20CA2054), Takeda Science Foundation, Mitsubishi Foundation, and the Bioinformatics Initiative of Osaka University Graduate School of Medicine, Osaka University. The funding agencies had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. This study was approved by the ethics committee of the Keio University School of Medicine (20200061) and affiliated institutes. We would like to thank all participants involved in this study and all members of the Japan COVID-19 task force regularly engaged in clinical and research work on COVID-19. All members contributed to this study. Conceptualization: M.W. K.M. S.C. H.N. T.A. H.K. M.I. N.H. and K.F. Data curation: M.W. H.T. H.L. A.M. S.O. K.N. M.W. and T.K. Formal analysis: M.W. K.M. S.C. Methodology: M.W. S.C. and H.N. Supervision: S.C. N.H. T.A. H.K, M.I. N.H. N.H. T.U. S.U. T.I. K.A. F.S. T.Y. Y.N. Y.M. Y.S. K.M. Y.O. R.K. Y.K. A.K. S.I. S.M. S.O. T.K. and K.F. Visualization: S.C. H.N. and T.A. Writing—original draft: W.M. K.M. T.A. S.C. and H.N. Writing—reviewing and editing: W.M. K.M. T.A. S.C. N.H. H.K, M.I. N.H. N.H. T.U. S.U. T.I. K.A. F.S. T.Y. Y.N. Y.M. Y.S. K.M. Y.O. R.K. Y.K. A.K. S.I. S.M. S.O. T.K. and K.F.
Publisher Copyright:
© 2022 The Authors
PY - 2023/3
Y1 - 2023/3
N2 - Objectives: Smoking and chronic obstructive pulmonary disease (COPD) are risk factors for severe COVID-19. However, limited literature exists on the effect of COPD and smoking on COVID-19 outcomes. This study examined the impact of smoking exposure in pack-years (PY) and COPD on COVID-19 outcomes among smokers in Japan. Methods: The study included 1266 smokers enrolled by the Japan COVID-19 task force between February 2020 and December 2021. PY and COPD status was self-reported by patients. Patients were classified into the non-COPD (n = 1151) and COPD (n = 115) groups; the non-COPD group was further classified into <10 PY (n = 293), 10-30 PY (n = 497), and >30 PY (n = 361). The study outcome was the need for invasive mechanical ventilation (IMV). Results: The incidence of IMV increased with increasing PY and was highest in the COPD group (<10 PY = 7.8%, 10-30 PY = 12.3%, >30 PY = 15.2%, COPD = 26.1%; P <0.001). A significant association was found for IMV requirement in the >30 PY and COPD groups through univariate (odds ratio [OR]: >30 PY = 2.11, COPD = 4.14) and multivariate (OR: >30 PY = 2.38; COPD = 7.94) analyses. Increasing PY number was also associated with increased IMV requirement in patients aged <65 years. Conclusion: Cumulative smoking exposure was positively associated with COVID-19 outcomes in smokers.
AB - Objectives: Smoking and chronic obstructive pulmonary disease (COPD) are risk factors for severe COVID-19. However, limited literature exists on the effect of COPD and smoking on COVID-19 outcomes. This study examined the impact of smoking exposure in pack-years (PY) and COPD on COVID-19 outcomes among smokers in Japan. Methods: The study included 1266 smokers enrolled by the Japan COVID-19 task force between February 2020 and December 2021. PY and COPD status was self-reported by patients. Patients were classified into the non-COPD (n = 1151) and COPD (n = 115) groups; the non-COPD group was further classified into <10 PY (n = 293), 10-30 PY (n = 497), and >30 PY (n = 361). The study outcome was the need for invasive mechanical ventilation (IMV). Results: The incidence of IMV increased with increasing PY and was highest in the COPD group (<10 PY = 7.8%, 10-30 PY = 12.3%, >30 PY = 15.2%, COPD = 26.1%; P <0.001). A significant association was found for IMV requirement in the >30 PY and COPD groups through univariate (odds ratio [OR]: >30 PY = 2.11, COPD = 4.14) and multivariate (OR: >30 PY = 2.38; COPD = 7.94) analyses. Increasing PY number was also associated with increased IMV requirement in patients aged <65 years. Conclusion: Cumulative smoking exposure was positively associated with COVID-19 outcomes in smokers.
KW - COPD
KW - COVID-19
KW - Invasive mechanical ventilation
KW - Smoking
UR - http://www.scopus.com/inward/record.url?scp=85146261617&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146261617&partnerID=8YFLogxK
U2 - 10.1016/j.ijid.2022.12.019
DO - 10.1016/j.ijid.2022.12.019
M3 - Article
C2 - 36563958
AN - SCOPUS:85146261617
SN - 1201-9712
VL - 128
SP - 121
EP - 127
JO - International Journal of Infectious Diseases
JF - International Journal of Infectious Diseases
ER -